Have you seen any increased dermatologic toxicity with whole breast or chest wall radiation if patients have received recent or concurrent pembrolizumab?

In the KEYNOTE study which established pembro as SOC, they did report small but numerically increased (3.8 vs 1%) grade 3 skin toxicity in pembro arm vs placebo. That’s why the guidelines say it’s safe to administer IO with RT as the above protocol after amendment allowed concurrent IO plus RT.

Meatt...

Yan et al., PMID 33137440

No